Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.

Journal of thrombosis and haemostasis : JTH - 1 Feb 2015

Chen W, Carvalho L P D, Chan M Y, Kini R M, Kang T S

Abstract excerpt

BACKGROUND: Bleeding remains a major limitation of standard anticoagulant drugs that target the extrinsic and common coagulation pathways. Recently, intrinsic coagulation factors are increasingly being investigated as alternative targets for developing anticoagulant drugs with lower bleeding risk. OBJECTIVES: Goals were to (i) identify novel anticoagulants selectively targeting intrinsic coagulation pathway and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding, Competitive
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bungarotoxins

Share to Carotid Stenosis

Share to Chlorides

Share to Ferric Compounds

Share to Partial Thromboplastin Time

Share to Prothrombin Time

Source

Identifiers

PMID: 25418421
DOI: 10.1111/jth.12797

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.PMID 25418421Read ↗

Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa InhibitorsSemantic proximity Read ↗

P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.Semantic proximity Read ↗

Structure and function of factor XI.Semantic proximity Read ↗

Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2.Semantic proximity Read ↗

Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases.Semantic proximity Read ↗

Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.Semantic proximity Read ↗

A First-in-human phase I study of an innovative selective inhibitor targeting coagulation factor XI/XIa in healthy volunteersSemantic proximity Read ↗

S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.Semantic proximity Read ↗

A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategiesSemantic proximity Read ↗

Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.Semantic proximity Read ↗

New insights into the biology of tissue factor pathway inhibitor.Semantic proximity Read ↗

Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.